FDA code for non-replicate crossover? [Software]

posted by d_labes  – Berlin, Germany, 2014-02-03 16:54 (4518 d 18:08 ago) – Posting: # 12324
Views: 32,691

Dear Helmut,

❝ ... But – hey! – that’s not the code given in FDA’s guidances. ;-)


where does your opinion came from?
So far as I know there is no code given in the FDA's guidances for non-replicate cross-over studies.

Moreover on page 10 of the 2001 Statistical guidance they recommend Proc GLM:
"General linear model procedures available in PROC GLM in SAS or equivalent software are preferred, although linear mixed-effects model procedures can also be indicated for analysis of nonreplicated crossover studies.

For example, for a conventional two-treatment, two-period, two-sequence (2 x 2) randomized crossover design, the statistical model typically includes factors accounting for the following sources of variation: sequence, subjects nested in sequences, period, and treatment. The Estimate statement in SAS PROC GLM, or equivalent statement in other software, should be used to obtain estimates for the adjusted differences between treatment means and the standard error associated with these differences."

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
166 visitors (0 registered, 166 guests [including 16 identified bots]).
Forum time: 12:02 CEST (Europe/Vienna)

Actually, science starts to become interesting
only where it ends.    Justus von Liebig

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5